Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4148MR)

This product GTTS-WQ4148MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4148MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12693MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ14044MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ7130MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ4575MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ11348MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ13284MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ4217MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ12000MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-121
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW